MX2020002046A - Forma cristalina del inhibidor de parp-1 y método de preparación de ésta. - Google Patents

Forma cristalina del inhibidor de parp-1 y método de preparación de ésta.

Info

Publication number
MX2020002046A
MX2020002046A MX2020002046A MX2020002046A MX2020002046A MX 2020002046 A MX2020002046 A MX 2020002046A MX 2020002046 A MX2020002046 A MX 2020002046A MX 2020002046 A MX2020002046 A MX 2020002046A MX 2020002046 A MX2020002046 A MX 2020002046A
Authority
MX
Mexico
Prior art keywords
preparation
crystal form
method therefor
parp
inhibitor
Prior art date
Application number
MX2020002046A
Other languages
English (en)
Inventor
Zhenjun Qiu
Wenhai Li
Quanliang Zhang
Zhengming Li
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2020002046A publication Critical patent/MX2020002046A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulgan en la presente invención una forma cristalina de un inhibidor de PARP-1 y un método de preparación de ésta; específicamente, se divulgan en la presente invención una forma cristalina A de 4-[[3-[[2-(trifluorometil)-5,6,7,8-tetrahidro-[1,2 ,4]triazolo[1,5-a]pirazina-7-il]carbonil]-4-fluorofenil]metil-1(2 H)-ftalazinona (fórmula I) y un método de preparación de ésta. (ver fórmula).
MX2020002046A 2017-08-24 2018-08-23 Forma cristalina del inhibidor de parp-1 y método de preparación de ésta. MX2020002046A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710737513 2017-08-24
PCT/CN2018/101875 WO2019037753A1 (zh) 2017-08-24 2018-08-23 一种parp-1抑制剂的晶型及其制备方法

Publications (1)

Publication Number Publication Date
MX2020002046A true MX2020002046A (es) 2020-09-17

Family

ID=65439965

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002046A MX2020002046A (es) 2017-08-24 2018-08-23 Forma cristalina del inhibidor de parp-1 y método de preparación de ésta.

Country Status (11)

Country Link
US (1) US11180505B2 (es)
EP (1) EP3674304B1 (es)
JP (1) JP2020531522A (es)
CN (1) CN110914272A (es)
AU (1) AU2018320562B2 (es)
CA (1) CA3073613A1 (es)
ES (1) ES2915830T3 (es)
MX (1) MX2020002046A (es)
MY (1) MY197303A (es)
TW (1) TWI765086B (es)
WO (1) WO2019037753A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115650988A (zh) * 2022-10-27 2023-01-31 江苏恒瑞医药股份有限公司 一种parp抑制剂的制备方法
WO2024109871A1 (zh) * 2022-11-23 2024-05-30 江苏恒瑞医药股份有限公司 一种含氮杂环类化合物的可药用盐、晶型及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404716B (zh) * 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
EP2190428A4 (en) 2007-08-21 2012-02-29 Merck Sharp & Dohme HETEROCYCLIC COMPOUNDS AS DIPEPTIDYLPEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372706A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN103476770B (zh) * 2010-11-25 2017-02-15 拉蒂欧制药有限责任公司 阿法替尼盐和多晶型物
CN105461697A (zh) * 2014-04-29 2016-04-06 中国医学科学院药物研究所 喹唑啉酮类parp-1抑制剂及含有它们的组合物和抗肿瘤用途
US20170204067A1 (en) * 2016-01-14 2017-07-20 Scinopharm Taiwan, Ltd. Crystalline forms of olaparib and manufacturing processes therefor

Also Published As

Publication number Publication date
TWI765086B (zh) 2022-05-21
RU2020110106A3 (es) 2021-12-24
AU2018320562A1 (en) 2020-03-12
MY197303A (en) 2023-06-12
US11180505B2 (en) 2021-11-23
JP2020531522A (ja) 2020-11-05
CA3073613A1 (en) 2019-02-28
RU2020110106A (ru) 2021-09-14
TW201912646A (zh) 2019-04-01
EP3674304A4 (en) 2020-12-16
EP3674304B1 (en) 2022-04-13
AU2018320562B2 (en) 2022-09-01
US20200291031A1 (en) 2020-09-17
EP3674304A1 (en) 2020-07-01
CN110914272A (zh) 2020-03-24
WO2019037753A1 (zh) 2019-02-28
ES2915830T3 (es) 2022-06-27

Similar Documents

Publication Publication Date Title
MY192059A (en) Heterocyclic amides as kinase inhibitors
MX2020011250A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
MX351848B (es) Formas cristalinas de inhibidor del factor xia.
WO2016034591A3 (en) Mutant csgg pores
WO2016011390A8 (en) Irak4 inhibiting agents
GEP20207111B (en) Heteroaryl compounds for kinase inhibition
MX2016009135A (es) Heteroarilos y usos de estos.
WO2014011911A3 (en) Irak inhibitors and uses thereof
WO2006091770A3 (en) Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
EP3405192A4 (en) INHIBITORS OF BRUTON TYROSINE KINASE
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX2014001879A (es) Aminoquinazolinas como inhibidores de quinasa.
UA85505C2 (en) Kinase inhibitors
EP3601264A4 (en) INHIBITORS OF BRUTON TYROSIN KINASE
EP3666770A4 (en) NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS
WO2012001093A3 (en) Liquid formulations of rupatadine fumarate
MX2020002046A (es) Forma cristalina del inhibidor de parp-1 y método de preparación de ésta.
EP3448852A4 (en) NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF TYROSINE KINASE BCR-ABL
EP3366817A4 (en) BASE SUBSTRATE, METHOD FOR MANUFACTURING BASE SUBSTRATE, AND PROCESS FOR MANUFACTURING GROUP 13 NITRIDE CRYSTAL
WO2014076568A3 (en) Pharmaceutical compositions of cetp inhibitors
PH12020551465A1 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
MX2017007955A (es) Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas.
MY189557A (en) Pyridone compound as c-met inhibitor